Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-α in a hemodialysis patient

Hepatology Research

Volumn 39, Issue 4, 2009, Pages 415-420

  Katamura, Yoshio ^a   Aikata, Hiroshi ^a   Kimura, Yuki ^a   Azakami, Takahiro ^a   Kawaoka, Tomokazu ^a   Takaki, Shintaro ^a   Waki, Koji ^a   Hiramatsu, Akira ^a   Kawakami, Yoshiiku ^a   Takahashi, Shoichi ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Extrahepatic metastases; Hemodialysis; Hepatocellular carcinoma; Interferon; Pulmonary metastasis; Systemic combination chemotherapy

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ALPHA2B INTERFERON; UFT;

ABSENCE OF SIDE EFFECTS; ADULT; ANOREXIA; ARTICLE; CANCER RELAPSE; CASE REPORT; CHEMOEMBOLIZATION; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE INCREASE; DRUG RESPONSE; HEMODIALYSIS; HEPATITIS C; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; NEUTROPENIA; PLEURA EFFUSION; PLEURISY; PRIORITY JOURNAL;

EID: 63649164307     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00448.x     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Uka K, Aikata H, Takaki S et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13: 414-20.
3. Natsuizaka M, Omura T, Akaike T et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005; 20: 1781-7.
4. Okusaka T, Okada S, Ishii H et al. Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 1997; 44: 251-7.
5. Miyamoto A, Umeshita K, Sakon M et al. Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 2000; 15: 1447-51.
6. Anami Y, Oguma S, Matsuda Y et al. [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/CDDP therapy.] Gan To Kagaku Ryoho 2005; 32: 1977-80 (in Japanese).
7. Patt YZ, Hassan MM, Lozano RD et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21: 421-7.
8. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005; 103: 756-62.
9. Uka K, Aikata H, Mori N et al. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology 2008; 75: 8-16.
10. Nakamura M, Nagano H, Marubashi S et al. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008; 112: 1765-71.
11. Hirata K, Horikoshi N, Aiba K et al. Pharmacokinetic study of S-1: A novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-5.
12. NCI Common Toxicity Criteria. http://ctep.cancer.gov/reporting/ctc.html.
13. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
14. Tominaga K, Higuchi K, Okazaki H et al. Safety and efficacy of S-1, a novel oral fluorouracil anticancer drug, for a chronic renal failure patient maintained on hemodialysis. Oncology 2004; 66: 358-64.
15. Tanaka T, Fujita S, Tanaka N, Ooka M, Okajima S, Tanaka N. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis -assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM).] Gan To Kagaku Ryoho 2005; 32: 841-5 (in Japanese).
16. Sakamoto K, Arita S, Hisikawa E et al. [Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis.] Gan To Kagaku Ryoho 1995; 22: 239-44 (in Japanese).
17. Pinedo HM, Peters GF. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
18. Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 1982; 9: 75-83.
19. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-5.
20. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-72.
21. Braybrooke JP, Propper DJ, O'Byrne KJ et al. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. Br J Cancer 2000; 83: 219-24.
22. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990; 50: 3473-86.
23. Yano H, Iemura A, Haramaki M et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999; 29: 1708-17.
24. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001; 33: 346-56.
25. Takaoka A, Hayakawa S, Yanai H et al. Integration of interferon-α/ β signalling to p53 responses in tumor suppression and antiviral defence. Nature 2003; 424: 516-23.
26. Ortaldo JR, Mantovani A, Hobbs D, Rubinstein M, Pestka S, Herberman RB. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer 1983; 31: 285-9.
27. + T cells. J Exp Med 1993; 178: 1655-63.
28. Uno K, Shimizu S, Ido M et al. Direct and indirect effects of interferon on in vivo murine tumor cell growth. Cancer Res 1985; 45: 1320-7.
29. Uka K, Aikata H, Takaki S et al. Pre-treatment predictor of response, time to progression and survival to intraarterial 5-fluorouracil/ interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42: 845-53.
30. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-6.
31. Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer 2002; 95: 588-95.
32. Lai YC, Shih CY, Jeng CM et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003; 9: 2666-70.
33. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin, and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55: 39-47.
34. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
35. Ota H, Nagano H, Sakon M et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-a and intra-arterial 5-fluorouracil: Role of type I interferon receptor expression. Br J Cancer 2005; 93: 557-64.
36. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.
37. Kogure T, Ueno Y, Iwasaki T, Shimosegawa T. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol 2004; 53: 296-304.
38. Nishiyama M, Yamamoto W, Park JS et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 2620-8.